• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Philip Morris International Inc

    11/8/24 8:46:39 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-33708
    Issuer: Philip Morris International Inc.
    Exchange: NEW YORK STOCK EXCHANGE LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 677 Washington Blvd
    Stamford CONNECTICUT 06901
    Telephone number: (917) 663-2000
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    0.625% Notes due 2024
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2024-11-08 By Emily Fuhrman Analyst, Regulation
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    1/20/2026$180.00Buy → Hold
    Jefferies
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    More analyst ratings

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman Calantzopoulos Andre was granted 40,052 shares, increasing direct ownership by 7% to 602,403 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/9/26 4:16:34 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Group Controller Dobrowolski Reginaldo was granted 6,538 shares, increasing direct ownership by 28% to 26,392 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/9/26 4:16:27 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Group CEO PMI Olczak Jacek was granted 171,039 shares, increasing direct ownership by 31% to 718,465 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/9/26 4:16:51 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, and Group Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2026 Consumer Analyst Group of New York (CAGNY) Conference at approximately 10:00 a.m. ET. The live webcast and presentation slides will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The presentation will cover: How a transformed PMI is leading the industry in an evolving operating environment; The success and future opportu

    2/18/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International to Present at 2026 CAGNY Conference

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast of a presentation by Jacek Olczak, Group CEO PMI, and Emmanuel Babeau, Group Chief Financial Officer, at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 18, 2026, at 10:00 a.m. ET. The live webcast and presentation slides will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading internati

    2/11/26 8:17:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

    Delivers Full Year 2025 Reported Diluted EPS of $7.26 compared to $4.52 in 2024 and Adjusted Diluted EPS of $7.54, Representing Growth of 14.8%, and 14.2% on a Currency-Neutral Basis; Provides 2026 - 2028 Growth Targets Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 fourth quarter results.1 "We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, including close to $17 billion from our smoke-free business, and very good operating margin expansion," said Jacek Olczak, Group CEO PMI. "With excellent results in 2024 and 2025, we have delivered our three-year CA

    2/6/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Philip Morris International downgraded by Jefferies with a new price target

    Jefferies downgraded Philip Morris International from Buy to Hold and set a new price target of $180.00

    1/20/26 9:10:49 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    SEC Filings

    View All

    Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    2/18/26 10:04:09 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    2/18/26 7:04:54 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-3ASR filed by Philip Morris International Inc

    S-3ASR - Philip Morris International Inc. (0001413329) (Filer)

    2/6/26 4:10:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

    The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE:PM) today released a new white paper, "Human Cognition: The Next Frontier?", inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the "superskill" of the future, driving progress in an era of human-machine collaboration. As AI automates routine ta

    1/20/26 5:03:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, and Group Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2026 Consumer Analyst Group of New York (CAGNY) Conference at approximately 10:00 a.m. ET. The live webcast and presentation slides will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The presentation will cover: How a transformed PMI is leading the industry in an evolving operating environment; The success and future opportu

    2/18/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

    Delivers Full Year 2025 Reported Diluted EPS of $7.26 compared to $4.52 in 2024 and Adjusted Diluted EPS of $7.54, Representing Growth of 14.8%, and 14.2% on a Currency-Neutral Basis; Provides 2026 - 2028 Growth Targets Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 fourth quarter results.1 "We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, including close to $17 billion from our smoke-free business, and very good operating margin expansion," said Jacek Olczak, Group CEO PMI. "With excellent results in 2024 and 2025, we have delivered our three-year CA

    2/6/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.47 per common share, payable on January 14, 2026, to shareholders of record as of December 26, 2025. The ex-dividend date is December 26, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio prim

    12/12/25 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care